Another approach involved the expression of anti-HER2 Trastuzumab light chains 1 and 2 fused to CD81 and tagged with a GFP reporter in HEK293T cells, yielding EVs capable of targeting HER2-expressing breast cancer cells [98]. This evidence concerns the gene ERBB2 and breast cancer.